CGI Pharmaceuticals is discovering and developing breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics expertise. Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds, all of which were designed and synthesized by CGI.

Flagship General Partner Doug Cole is on the Board of Directors.

www.cgipharma.com